Molecular Partners (MOLN) Competitors

$3.92 +0.18 (+4.79%)

Closing price 03:59 PM Eastern

Extended Trading

$3.79 -0.13 (-3.29%)

As of 04:10 PM Eastern

MOLN vs. CTMX, ARVN, TLRY, PRME, and CRMD

Should you buy Molecular Partners stock or one of its competitors? MarketBeat compares Molecular Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Molecular Partners include CytomX Therapeutics (CTMX), Arvinas (ARVN), Tilray Brands (TLRY), Prime Medicine (PRME), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Molecular Partners compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

CytomX Therapeutics has higher revenue and earnings than Molecular Partners. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.39	-$17.37M	-$0.41	N/A
Molecular Partners	$5.65M	28.01	-$74.41M	-$1.94	N/A

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 222.24%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 113.70%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Molecular Partners has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Molecular Partners	N/A	-66.62%	-54.85%

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CytomX Therapeutics had 3 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for CytomX Therapeutics and 0 mentions for Molecular Partners. CytomX Therapeutics' average media sentiment score of 0.50 beat Molecular Partners' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Positive
Molecular Partners	Neutral

CytomX Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

CytomX Therapeutics beats Molecular Partners on 14 of the 17 factors compared between the two stocks.

How does Molecular Partners compare to Arvinas?

Molecular Partners (NASDAQ:MOLN) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Molecular Partners has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.01	-$74.41M	-$1.94	N/A
Arvinas	$262.60M	2.24	-$80.80M	-$3.32	N/A

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 113.70%. Arvinas has a consensus target price of $14.69, suggesting a potential upside of 61.28%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Arvinas	3 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

Molecular Partners has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Arvinas	-247.54%	-44.38%	-28.38%

In the previous week, Arvinas had 12 more articles in the media than Molecular Partners. MarketBeat recorded 12 mentions for Arvinas and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.00 beat Arvinas' score of -0.19 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Neutral
Arvinas	Neutral

Summary

Arvinas beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Tilray Brands had 5 more articles in the media than Molecular Partners. MarketBeat recorded 5 mentions for Tilray Brands and 0 mentions for Molecular Partners. Tilray Brands' average media sentiment score of 0.41 beat Molecular Partners' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Neutral
Molecular Partners	Neutral

Molecular Partners has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Molecular Partners	N/A	-66.62%	-54.85%

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Molecular Partners has lower revenue, but higher earnings than Tilray Brands. Molecular Partners is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A
Molecular Partners	$5.65M	28.01	-$74.41M	-$1.94	N/A

Tilray Brands has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Tilray Brands presently has a consensus price target of $11.50, suggesting a potential upside of 110.43%. Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 113.70%. Given Molecular Partners' higher possible upside, analysts plainly believe Molecular Partners is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Tilray Brands beats Molecular Partners on 8 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Prime Medicine?

Molecular Partners (NASDAQ:MOLN) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Prime Medicine had 1 more articles in the media than Molecular Partners. MarketBeat recorded 1 mentions for Prime Medicine and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.00 equaled Prime Medicine'saverage media sentiment score.

Company	Overall Sentiment
Molecular Partners	Neutral
Prime Medicine	Neutral

Molecular Partners has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Molecular Partners' return on equity of -66.62% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Molecular Partners has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.01	-$74.41M	-$1.94	N/A
Prime Medicine	$4.63M	114.89	-$201.14M	-$1.23	N/A

Molecular Partners currently has a consensus target price of $8.38, suggesting a potential upside of 113.70%. Prime Medicine has a consensus target price of $7.65, suggesting a potential upside of 159.76%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 22.7% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Summary

Prime Medicine beats Molecular Partners on 10 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to CorMedix?

Molecular Partners (NASDAQ:MOLN) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CorMedix has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	28.01	-$74.41M	-$1.94	N/A
CorMedix	$311.71M	2.03	$163.05M	$2.13	3.78

Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 113.70%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 86.22%. Given Molecular Partners' higher possible upside, equities research analysts plainly believe Molecular Partners is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, CorMedix had 16 more articles in the media than Molecular Partners. MarketBeat recorded 16 mentions for CorMedix and 0 mentions for Molecular Partners. CorMedix's average media sentiment score of 0.82 beat Molecular Partners' score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.

Company	Overall Sentiment
Molecular Partners	Neutral
CorMedix	Positive

CorMedix has a net margin of 45.25% compared to Molecular Partners' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
CorMedix	45.25%	45.57%	24.76%

Molecular Partners has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Summary

CorMedix beats Molecular Partners on 13 of the 16 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$158.25M	$3.36B	$6.34B	$12.28B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-2.02	19.02	20.92	25.48
Price / Sales	28.01	278.81	521.15	73.33
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.81	6.90	9.98	7.01
Net Income	-$74.41M	$24.23M	$3.55B	$335.16M
7 Day Performance	2.06%	0.65%	0.40%	-0.30%
1 Month Performance	-12.70%	-0.55%	-0.04%	1.14%
1 Year Performance	-1.04%	63.42%	34.95%	34.69%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	2.2783 of 5 stars	$3.92 +4.8%	$8.38 +113.7%	-5.1%	$158.25M	$5.65M	N/A	180	High Trading Volume
CTMX CytomX Therapeutics	3.0481 of 5 stars	$3.79 -2.3%	$12.78 +237.1%	+80.6%	$645.02M	$76.20M	N/A	170	Analyst Upgrade
ARVN Arvinas	2.4868 of 5 stars	$9.87 +3.1%	$15.14 +53.4%	+37.0%	$636.81M	$262.60M	N/A	420	Analyst Downgrade
TLRY Tilray Brands	3.1729 of 5 stars	$5.46 +0.9%	$11.50 +110.6%	+19.5%	$636.36M	$821.31M	N/A	2,842
PRME Prime Medicine	1.8285 of 5 stars	$3.27 -0.9%	$7.38 +125.5%	N/A	$590.62M	$4.03M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. CTMX, ARVN, TLRY, PRME, and CRMD

How does Molecular Partners compare to CytomX Therapeutics?

Summary

How does Molecular Partners compare to Arvinas?

Summary

How does Molecular Partners compare to Tilray Brands?

Summary

How does Molecular Partners compare to Prime Medicine?

Summary

How does Molecular Partners compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. CTMX, ARVN, TLRY, PRME, and CRMD

How does Molecular Partners compare to CytomX Therapeutics?

Which has better earnings & valuation, CTMX or MOLN?

Do analysts rate CTMX or MOLN?

Is CTMX or MOLN more profitable?

Do institutionals and insiders hold more shares of CTMX or MOLN?

Does the media favor CTMX or MOLN?

Which has more risk and volatility, CTMX or MOLN?

Summary

How does Molecular Partners compare to Arvinas?

Which has more volatility & risk, MOLN or ARVN?

Do institutionals & insiders have more ownership in MOLN or ARVN?

Which has higher valuation & earnings, MOLN or ARVN?

Do analysts prefer MOLN or ARVN?

Is MOLN or ARVN more profitable?

Does the media refer more to MOLN or ARVN?

Summary

How does Molecular Partners compare to Tilray Brands?

Does the media favor TLRY or MOLN?

Is TLRY or MOLN more profitable?

Do institutionals and insiders have more ownership in TLRY or MOLN?

Which has better valuation & earnings, TLRY or MOLN?

Which has more volatility and risk, TLRY or MOLN?

Do analysts prefer TLRY or MOLN?

Summary

How does Molecular Partners compare to Prime Medicine?

Does the media favor MOLN or PRME?

Is MOLN or PRME more profitable?

Which has higher earnings and valuation, MOLN or PRME?

Do analysts rate MOLN or PRME?

Do insiders and institutionals have more ownership in MOLN or PRME?

Which has more risk & volatility, MOLN or PRME?

Summary

How does Molecular Partners compare to CorMedix?

Do insiders & institutionals believe in MOLN or CRMD?

Which has better earnings & valuation, MOLN or CRMD?

Do analysts recommend MOLN or CRMD?

Does the media refer more to MOLN or CRMD?

Is MOLN or CRMD more profitable?

Which has more risk & volatility, MOLN or CRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools